Skip to main content
Premium Trial:

Request an Annual Quote

Wayfinder Biosciences Raises $3.5M in Seed Funding

NEW YORK – Wayfinder Biosciences said on Monday that it has raised $3.5 million in seed financing.

The Seattle-based firm is engineering RNA molecules for use in diagnostics and therapeutics. In a statement, the firm said it would use the funds to scale its RNA design platform, with a focus on expanding into therapeutics.

Notation Capital and Divergent Capital led the round, joined by IndieBio, BoxOne Ventures, Notley Biosciences, Reinforced Ventures, Genesis Consortium, Conscience VC, Social Starts Health and Happiness, Overlap Holdings, and other investors.

Wayfinder's "impressive RNA design platform is the key to driving rapid breakthroughs in the nascent field of RNA molecular detectors and therapeutics," Divergent Capital Cofounder and General Partner Lucy Wang said in a statement. "While a typical company in this space goes through years of development and iteration to reach the first application, there are already a number of use cases that the team is working on with customers to generate commercial value from day one."

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.